EGFR and cancer: In a case report of a patient with recurrent/metastatic oral squamous cell carcinoma, the efficacy of the PD-1 inhibitor Nivolumab in combination with the anti-EGFR antibody Nimotuzumab and radiotherapy has also been described in terms of decreased metabolic activity in cancer cells, reduction of lung lesions dimensions, progression-free survival and tolerable safety profile (162).